Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

329 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeting claudin-4 enhances chemosensitivity of pancreatic ductal carcinomas.
Sasaki T, Fujiwara-Tani R, Kishi S, Mori S, Luo Y, Ohmori H, Kawahara I, Goto K, Nishiguchi Y, Mori T, Sho M, Kondo M, Kuniyasu H. Sasaki T, et al. Among authors: sho m. Cancer Med. 2019 Nov;8(15):6700-6708. doi: 10.1002/cam4.2547. Epub 2019 Sep 9. Cancer Med. 2019. PMID: 31498559 Free PMC article.
Clinical importance of B7-H3 expression in human pancreatic cancer.
Yamato I, Sho M, Nomi T, Akahori T, Shimada K, Hotta K, Kanehiro H, Konishi N, Yagita H, Nakajima Y. Yamato I, et al. Among authors: sho m. Br J Cancer. 2009 Nov 17;101(10):1709-16. doi: 10.1038/sj.bjc.6605375. Epub 2009 Oct 20. Br J Cancer. 2009. PMID: 19844235 Free PMC article.
[A case of postoperative multiple liver metastases of pancreatic cancer successfully treated by combination chemotherapy with weekly high-dose 5-FU hepatic arterial infusion plus systemic infusion of gemcitabine].
Doh J, Sho M, Tanaka T, Yamada T, Nomi T, Akahori T, Yamato I, Nishiofuku H, Tamamoto T, Hasegawa M, Kichikawa K, Nakajima Y. Doh J, et al. Among authors: sho m. Gan To Kagaku Ryoho. 2009 Nov;36(12):2087-9. Gan To Kagaku Ryoho. 2009. PMID: 20037332 Japanese.
Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
Yanagimoto H, Satoi S, Sho M, Akahori T, Yamamoto T, Hirooka S, Yamaki S, Kotsuka M, Ryota H, Kinoshita S, Nishiwada S, Nagai M, Ikeda N, Tsuta K, Nakajima Y, Kon M. Yanagimoto H, et al. Among authors: sho m. Cancer Chemother Pharmacol. 2016 Jan;77(1):35-41. doi: 10.1007/s00280-015-2928-z. Epub 2015 Dec 8. Cancer Chemother Pharmacol. 2016. PMID: 26645403 Clinical Trial.
Phase II Study of the Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in Patients with Unresectable Pancreatic Ductal Adenocarcinoma.
Akahori T, Sho M, Yanagimoto H, Satoi S, Nagai M, Nishiwada S, Nakagawa K, Nakamura K, Yamamoto T, Hirooka S, Yamaki S, Ikeda N. Akahori T, et al. Among authors: sho m. Oncologist. 2019 Jun;24(6):749-e224. doi: 10.1634/theoncologist.2018-0900. Epub 2019 Jan 24. Oncologist. 2019. PMID: 30679316 Free PMC article. Clinical Trial.
329 results